Nemaura Medical (NSDQ:NMRD) said today that it placed an initial order to its UK-based contract manufacturer for 12,500 rechargeable transmitters, designed as part of the company’s sugarBeat glucose monitoring systems.
Nemaura is readying for the commercial launch of its sugarBeat glucose monitor, pending CE Mark approval in the European Union. The device consists of a disposable, adhesive patch that connects to a transmitter and sends glucose data to a mobile app every five minutes.
Get the full story at our sister site, Drug Delivery Business News.
The post Nemaura Medical gears up to commercialize glucose monitor appeared first on MassDevice.
from MassDevice https://ift.tt/2LrnN8s
Cap comentari:
Publica un comentari a l'entrada